Policy | February 02, 2024
Industry’s reaction to Union Budget 2024-25
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
Lays foundation stone of NIPER Hyderabad and NIPER Raebareli
Subscribe To Our Newsletter & Stay Updated
